Steven Gillis

Dr. Gillis is a Managing Director at ARCH Venture Partners, focused on the evaluation of new life science technologies and also on the development and growth of ARCH's biotechnology portfolio companies. Dr. Gillis was a founder and director of Corixa Corp. and served as the company’s Chief Executive Officer since inception and as its Chairman since January of 1999. Corixa was acquired by GlaxoSmithKline in July of 2005. Prior to starting Corixa, Dr. Gillis was a founder and director of Immunex Corp. From 1981 until his departure in 1994, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer, and Chief Executive Officer of Immunex’s Research and Development subsidiary. Dr. Gillis was interim Chief Executive Officer of Immunex Corp. following its majority purchase by American Cyanamid Co. and he remained a member of the Board of Directors until 1997. Immunex was acquired by Amgen Inc. in 2002. Dr. Gillis is an immunologist by training and is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products, including Leukine®, Prokine®, Enbrel®, and Bexxar®.

Dr. Gillis received his B.A. from Williams College in 1975 and his PhD from Dartmouth College in 1978.